Illumina wins chance to battle Complete Genomics over patents

Illumina ($ILMN), a gene sequencer and diagnostics company, will renew a push to continue its patent fight against Complete Genomics ($GNOM). The U.S. District Court for the Northern District of California granted the company's request to file a motion seeking reconsideration of its October ruling invalidating patent claims against Complete Genomics.  Previously, the court invalidated two of Illumina's claims. The continued court fight comes after Complete Genomics rebuffed a takeover bid from Illumina in favor of a Chinese suitor. Release

Suggested Articles

Encellin is working on a cell pouch that cuts down on the scarring that comes with encapsulated cell transplants.

Medtronic aims to boost its growth with a suite of new products including surgical robotics, diabetes hardware and miniaturized pacemakers.

Boston Scientific’s deep brain stimulation implant for treating Parkinson’s disease has been approved by the FDA as safe to use within an MRI.